Randomized Study of Basal-Bolus Insulin Therapy in the Inpatient Management of Patients With Type 2 Diabetes Undergoing General Surgery (RABBIT 2 Surgery)
-
- Guillermo E. Umpierrez
- Department of Medicine, Emory University, Atlanta, Georgia
-
- Dawn Smiley
- Department of Medicine, Emory University, Atlanta, Georgia
-
- Sol Jacobs
- Department of Medicine, Emory University, Atlanta, Georgia
-
- Limin Peng
- Rollins School of Public Health, Emory University, Atlanta, Georgia
-
- Angel Temponi
- Department of Medicine, Emory University, Atlanta, Georgia
-
- Patrick Mulligan
- Department of Medicine, Emory University, Atlanta, Georgia
-
- Denise Umpierrez
- Department of Medicine, Emory University, Atlanta, Georgia
-
- Christopher Newton
- Department of Medicine, Emory University, Atlanta, Georgia
-
- Darin Olson
- Department of Medicine, Emory University, Atlanta, Georgia
-
- Monica Rizzo
- Department of Surgery, Emory University, Atlanta, Georgia
書誌事項
- 公開日
- 2011-01-20
- 権利情報
-
- http://creativecommons.org/licenses/by-nc-nd/3.0/
- DOI
-
- 10.2337/dc10-1407
- 公開者
- American Diabetes Association
この論文をさがす
説明
<jats:sec> <jats:title>OBJECTIVE</jats:title> <jats:p>The optimal treatment of hyperglycemia in general surgical patients with type 2 diabetes mellitus is not known.</jats:p> </jats:sec> <jats:sec> <jats:title>RESEARCH DESIGN AND METHODS</jats:title> <jats:p>This randomized multicenter trial compared the safety and efficacy of a basal-bolus insulin regimen with glargine once daily and glulisine before meals (n = 104) to sliding scale regular insulin (SSI) four times daily (n = 107) in patients with type 2 diabetes mellitus undergoing general surgery. Outcomes included differences in daily blood glucose (BG) and a composite of postoperative complications including wound infection, pneumonia, bacteremia, and respiratory and acute renal failure.</jats:p> </jats:sec> <jats:sec> <jats:title>RESULTS</jats:title> <jats:p>The mean daily glucose concentration after the 1st day of basal-bolus insulin and SSI was 145 ± 32 mg/dL and 172 ± 47 mg/dL, respectively (P < 0.01). Glucose readings <140 mg/dL were recorded in 55% of patients in basal-bolus and 31% in the SSI group (P < 0.001). There were reductions with basal-bolus as compared with SSI in the composite outcome [24.3 and 8.6%; odds ratio 3.39 (95% CI 1.50–7.65); P = 0.003]. Glucose <70 mg/dL was reported in 23.1% of patients in the basal-bolus group and 4.7% in the SSI group (P < 0.001), but there were no significant differences in the frequency of BG <40 mg/dL between groups (P = 0.057).</jats:p> </jats:sec> <jats:sec> <jats:title>CONCLUSIONS</jats:title> <jats:p>Basal-bolus treatment with glargine once daily plus glulisine before meals improved glycemic control and reduced hospital complications compared with SSI in general surgery patients. Our study indicates that a basal-bolus insulin regimen is preferred over SSI in the hospital management of general surgery patients with type 2 diabetes.</jats:p> </jats:sec>
収録刊行物
-
- Diabetes Care
-
Diabetes Care 34 (2), 256-261, 2011-01-20
American Diabetes Association